ebulized furosemide as adjunctive therapy in patients with stable chronic obstructive pulmonary disease : A randomized controlled trial
Not Applicable
- Conditions
- Respiratory
- Registration Number
- PACTR202106917652038
- Lead Sponsor
- Medical Research Institute Alexandria University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Stable (Not exacerbating) COPD patients documented by the pulmonologist
- FEV1, FVC, (FEV1/FVC) less than 70%
- Irreversible response to inhaled ß-agonist (FEV1i ncrease <12% and <200 cc after15min from baseline)
- Symptoms last about 5 years of breathlessness and, productive cough
Exclusion Criteria
Patients with history of other lung diseases such as pneumonia, idiopathic pulmonary fibrosis, consolidation, congestive heart failure, exacerbated, asthma or asthma-COPD overlap.
Smoking more than 15 packs/year
using furosemide and other diuretics
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method forced expiratory volume/second (FEV1)<br>;Forced vital capacity (FVC);FEV1/FVC<br>
- Secondary Outcome Measures
Name Time Method Modified Medical Research Council (mMRC)<br>;COPD assessment test (CAT)<br>